151 related articles for article (PubMed ID: 20151048)
21. Phase I Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Local or Metastatic Esophageal Cancer.
Iwasaki K; Osaka Y; Tachibana S; Suda T; Ota Y; Hoshino S; Tsuchida A
Anticancer Res; 2016 Mar; 36(3):987-94. PubMed ID: 26976988
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
24. A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma.
Bazarbashi S; Rahal M; Raja MA; El Weshi A; Pai C; Ezzat A; Ajarim D; Memon M; Al Fadda M
Chemotherapy; 2002 Sep; 48(4):211-6. PubMed ID: 12218269
[TBL] [Abstract][Full Text] [Related]
25. TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Omatsu H; Kuwahara A; Yamamori M; Fujita M; Okuno T; Miki I; Tamura T; Nishiguchi K; Okamura N; Nakamura T; Azuma T; Hirano T; Ozawa K; Hirai M
Int J Med Sci; 2013; 10(12):1755-60. PubMed ID: 24151445
[TBL] [Abstract][Full Text] [Related]
26. Chemoradiotherapy of esophageal carcinoma.
Poplin EA; Khanuja PS; Kraut MJ; Herskovic AM; Lattin PB; Cummings G; Gaspar LE; Kinzie JL; Steiger Z; Vaitkevicius VK
Cancer; 1994 Aug; 74(4):1217-24. PubMed ID: 8055441
[TBL] [Abstract][Full Text] [Related]
27. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Higuchi K; Koizumi W; Tanabe S; Sasaki T; Katada C; Ishiyama H; Hayakawa K
Radiother Oncol; 2008 Jun; 87(3):398-404. PubMed ID: 18405987
[TBL] [Abstract][Full Text] [Related]
28. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
Sakaeda T; Yamamori M; Kuwahara A; Hiroe S; Nakamura T; Okumura K; Okuno T; Miki I; Chayahara N; Okamura N; Tamura T
Ther Drug Monit; 2008 Aug; 30(4):497-503. PubMed ID: 18641541
[TBL] [Abstract][Full Text] [Related]
29. Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma.
Miki I; Tamura T; Nakamura T; Makimoto H; Hamana N; Uchiyama H; Shirasaka D; Morita Y; Yamada H; Aoyama N; Sakaeda T; Okumura K; Kasuga M
Ther Drug Monit; 2005 Jun; 27(3):369-74. PubMed ID: 15905809
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
[TBL] [Abstract][Full Text] [Related]
31. Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil.
Sai H; Mitsumori M; Yamauchi C; Araki N; Okumura S; Nagata Y; Nishimura Y; Hiraoka M
Int J Clin Oncol; 2004 Jun; 9(3):149-53. PubMed ID: 15221597
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Minegaki T; Kuwahara A; Yamamori M; Nakamura T; Okuno T; Miki I; Omatsu H; Tamura T; Hirai M; Azuma T; Sakaeda T; Nishiguchi K
Int J Med Sci; 2014; 11(4):321-6. PubMed ID: 24578608
[TBL] [Abstract][Full Text] [Related]
33. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Kumekawa Y; Kaneko K; Ito H; Kurahashi T; Konishi K; Katagiri A; Yamamoto T; Kuwahara M; Kubota Y; Muramoto T; Mizutani Y; Imawari M
J Gastroenterol; 2006 May; 41(5):425-32. PubMed ID: 16799883
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.
Osaka Y; Shinohara M; Hoshino S; Ogata T; Takagi Y; Tsuchida A; Aoki T
Anticancer Res; 2011 Feb; 31(2):633-8. PubMed ID: 21378349
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
[TBL] [Abstract][Full Text] [Related]
36. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
37. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
38. Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.
Osawa S; Furuta T; Sugimoto K; Kosugi T; Terai T; Yamade M; Takayanagi Y; Nishino M; Hamaya Y; Kodaira C; Yamada T; Iwaizumi M; Takagaki K; Yoshida K; Kanaoka S; Ikuma M
BMC Cancer; 2009 Nov; 9():408. PubMed ID: 19930599
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer.
Hihara J; Yoshida K; Hamai Y; Emi M; Yamaguchi Y; Wadasaki K
Anticancer Res; 2007; 27(4C):2597-603. PubMed ID: 17695421
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study.
Zhao T; Chen H; Zhang T
Med Oncol; 2012 Dec; 29(5):3017-23. PubMed ID: 22476809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
